Newly developed retatrutide, a twin -action medication retatrutide targeting equally GLP-1 and GIP receptors, is creating considerable buzz within the medical community. Early clinical trials have revealed substantial reductions in overall mass and advancements in health markers for individuals with overweight. Experts believe this novel approach